Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer immunotherapy in patients with brain metastases

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Loss of Ambra1 promotes melanoma growth and invasion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy
Vol/bind67
Udgave nummer5
Sider (fra-til)703-711
Antal sider9
ISSN0340-7004
DOI
StatusUdgivet - maj 2018

ID: 54806559